AstraZeneca Investor Day Presentation Deck
Immune-mediated adverse events.
41
Event, n (%)
Patients with immune-
mediated event
Hepatic events
Diarrhea/colitis
Dermatitis/rash
Pancreatic events
Adrenal insufficiency
Hyperthyroid events
Hypothyroid events
Pneumonitis
Renal events
All grades
139 (35.8)
29 (7.5)
23 (5.9)
19 (4.9)
9 (2.3)
6 (1.5)
18 (4.6)
42 (10.8)
5 (1.3)
4 (1.0)
T300+D (n=388)
Grade 3 or 4
49 (12.6)
16 (4.1)
14 (3.6)
7 (1.8)
7 (1.8)
1 (0.3)
1 (0.3)
0
0
2 (0.5)
Received
high-dose
steroids
78 (20.1)
29 (7.5)
20 (5.2)
12 (3.1)
7 (1.8)
1 (0.3)
2 (0.5)
1 (0.3)
4 (1.0)
3 (0.8)
Leading to
discontinuation
22 (5.7)
9 (2.3)
5 (1.3)
2 (0.5)
0
0
0
0
1 (0.3)
2 (0.5)
All grades
64 (16.5)
26 (6.7)
3 (0.8)
3 (0.8)
2 (0.5)
6 (1.5)
4 (1.0)
19 (4.9)
3 (0.8)
0
Durvalumab (n=388)
Grade 3 or 4
25 (6.4)
17 (4.4)
1 (0.3)
1 (0.3)
1 (0.3)
3 (0.8)
0
0
1 (0.3)
0
Received
high-dose
steroids
37 (9.5)
25 (6.4)
2 (0.5)
3 (0.8)
2 (0.5)
3 (0.8)
0
0
3 (0.8)
0
Leading to
discontinuation
10 (2.6)
5 (1.3)
1 (0.3)
1 (0.3)
0
0
0
0
2 (0.5)
0
BView entire presentation